Lovende oppdaterte foreløpige overlevelsesdata, en dobling sammenlignet med standardbehandling rapportert for AML pasienter med tilbakefall Bergen, Norge, 11. juni 2021 - BerGenBio ASA (OSE:BGBIO), et biofarmasøytisk selskap i klinisk fase som utvikler nye, selektive hemmere av AXL-kinase for krefttyper med behov for forbedret behandlingstilbud, vil presentere oppdaterte foreløpige overlevelsesdata fra den pågående fase-II studien av bemcentinib (BGBC003) i kombinasjon med … Read more
Encouraging updated preliminary survival data more than double standard of care reported in relapsed AML patients Bergen, Norway, 11 June 2021 - BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, will present updated preliminary survival data from the ongoing Phase II study of bemcentinib (BGBC003) in combination with low dose … Read more
Bergen, Norway, 10 June 2021 - BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, today announces that an analysis of its Phase II clinical trial of bemcentinib, a first-in-class selective oral AXL inhibitor, in hospitalised COVID-19 patients has been selected as a late-breaking abstract at the European Congress … Read more
Dette er den første regulatoriske anerkjennelsen av AXL-positive pasienter som en målrettet pasientpopulasjon. Bergen, Norge, 8. juni 2021 - BerGenBio ASA (OSE:BGBIO), et biofarmasøytisk selskap i klinisk fase som utvikler nye, selektive hemmere av AXL-kinase for krefttyper med behov for forbedret behandlingstilbud, kunngjør i dag at det amerikanske legemiddelverket (FDA) har gitt fast track status for bemcentinib i kombinasjon … Read more
First recognition by a regulator of AXL-positive patients as a target population Bergen, Norway, 08 June 2021 - BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, today announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for bemcentinib in combination with an anti-PD-(L)1 … Read more
Bergen, Norway, 7 June 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to present preclinical data on its first-in-class, fully humanised, therapeutic anti-AXL function blocking monoclonal antibody, tilvestamab, in chronic kidney disease at the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Virtual Congress. This … Read more
Bergen, Norway, 04 June 2021 - BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, today presents end-of-trial data from a Phase I/II study of bemcentinib in combination with erlotinib in patients with advanced non-small cell lung cancer (NSCLC) at the American Society of Clinical Oncology (ASCO) Annual Meeting. Study … Read more
Bergen, Norway, 21[st] May 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that BerGenBio CEO Mr. Richard Godfrey is presenting at the following virtual conference: ABGSC Life Science Summit, virtual Date: 25 May Live presentation at 10.30hrs CET The presentation … Read more
Bergen, Norway, 20 May 2021 - BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, will present an end-of-trial update from a Phase I/II study of bemcentinib in combination with erlotinib in patients with advanced non-small cell lung cancer (NSCLC) at the American Society of Clinical Oncology (ASCO) Annual Meeting. End of … Read more
Bergen, Norway, 19 May 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces its results for the first quarter of 2021. A presentation and live webcast by BerGenBio’s senior management will take place at 10.00 am CEST today, please see below for details. … Read more
soug@oncoinvent.com
Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.
Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997
mansson@oncoinvent.com
Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.
Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.